Does Centene Corporation Cover Ambien?

At a glance
- Generic zolpidem / covered on most Centene formularies at Tier 1 or Tier 2
- Brand Ambien / usually non-preferred or excluded; prior authorization often required
- Ambien CR (extended-release) / Tier 3 or higher; step therapy through immediate-release zolpidem first
- Typical Medicaid copay / $0 to $3 for generic zolpidem in most states
- Ambetter marketplace copay / $3 to $15 for Tier 1 generics (plan-dependent)
- WellCare Medicare copay / $0 to $10 at preferred pharmacies during the initial coverage phase
- Quantity limit / commonly 30 tablets per 30 days for zolpidem 5 mg or 10 mg
- Prior authorization turnaround / standard decision within 72 hours; urgent within 24 hours per federal rules
- Appeal window / 60 days from denial notice for most plan types
How Centene Corporation Structures Drug Coverage
Centene is the largest Medicaid managed care organization in the United States, serving over 27 million members across its subsidiary health plans [1]. The company operates under multiple brand names. Ambetter handles Affordable Care Act marketplace plans. WellCare manages Medicare Advantage and Medicare Part D. State-specific Medicaid contracts run under names like Peach State Health Plan (Georgia), Sunshine Health (Florida), and Magnolia Health (Mississippi).
Each subsidiary maintains its own formulary, but Centene's corporate pharmacy and therapeutics (P&T) committee sets a national preferred drug list that guides all subsidiary decisions [2]. Zolpidem tartrate immediate-release tablets appear on this national preferred list as a Tier 1 or Tier 2 generic. Brand-name Ambien does not.
This distinction matters for out-of-pocket cost. A Tier 1 generic on an Ambetter Silver plan may carry a $3 copay, while a non-preferred brand on Tier 3 could cost $50 or more per fill [3]. For Medicaid members, federal law caps copays at nominal amounts (typically $0 to $4 for generics), so the financial difference between tiers is smaller but still present [4].
The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline recommends cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment, with pharmacotherapy reserved for patients who do not respond adequately or lack access to CBT-I [5]. This guideline directly shapes how Centene's utilization management protocols treat sleep medication requests.
Generic Zolpidem: What Most Centene Members Actually Receive
Generic zolpidem is the version most Centene members will fill. That is by design. The FDA approved the first generic zolpidem tartrate tablets in April 2007, and multiple manufacturers now produce 5 mg and 10 mg immediate-release tablets [6]. Wholesale acquisition cost for a 30-day supply of generic zolpidem sits below $10, making it one of the least expensive prescription sleep aids available.
On Centene Medicaid managed care formularies, generic zolpidem is listed without prior authorization in the majority of state contracts. A 2023 analysis of Medicaid formulary restrictions across 37 state Medicaid managed care organizations found that zolpidem immediate-release was covered without prior authorization in 89% of plans reviewed [7]. Centene's Medicaid plans follow this pattern.
For Ambetter marketplace plans, generic zolpidem typically sits on Tier 1 (preferred generic). The copay ranges from $0 to $15 depending on the metal level selected. Bronze plans tend toward higher copays; Silver and Gold plans often have lower flat copays for Tier 1 drugs.
WellCare Medicare Part D plans place generic zolpidem on Tier 1 as well. During the initial coverage phase, preferred pharmacy copays run $0 to $10 for Tier 1 medications [8]. After reaching the coverage gap (the so-called "donut hole"), members pay no more than 25% of the negotiated price for generic drugs under the Inflation Reduction Act's $2,000 annual out-of-pocket cap that took effect in 2025 [9].
Quantity limits apply across all Centene plan types. The standard limit is 30 tablets per 30 days for zolpidem 5 mg or 10 mg. Some plans set a lower limit of 15 tablets per 30 days for new prescriptions, requiring documentation of ongoing need before approving a full month's supply.
Brand-Name Ambien and Ambien CR: Prior Authorization Rules
Brand-name Ambien (zolpidem tartrate immediate-release) and Ambien CR (zolpidem tartrate extended-release) face tighter restrictions on Centene formularies. Most Centene subsidiaries classify brand Ambien as "non-formulary" when a therapeutically equivalent generic exists. This means the plan will not cover brand Ambien unless the prescriber demonstrates medical necessity for the brand specifically.
Ambien CR is a different situation. The extended-release formulation does not have a direct generic equivalent in the same delivery system (though generic zolpidem ER tablets are available from several manufacturers). Centene plans that list zolpidem ER place it on Tier 2 or Tier 3, and most require step therapy: the member must first try and fail immediate-release zolpidem before the plan approves the extended-release version [10].
Prior authorization criteria for Ambien CR on Centene plans generally require documentation of three elements. The prescriber must show the member tried immediate-release zolpidem for at least 14 days. The prescriber must document that the member's primary complaint is sleep maintenance insomnia (waking during the night) rather than sleep onset insomnia alone. The prescriber must confirm the member does not have contraindications including severe hepatic impairment or concurrent use of other CNS depressants at high doses.
The FDA's 2013 safety communication lowered the recommended starting dose of zolpidem ER to 6.25 mg for all patients, with a particular emphasis on women, after pharmacokinetic data showed women clear zolpidem more slowly, leading to next-morning impairment [11]. Centene's prior authorization criteria reflect this labeling change, and requests for the 12.5 mg strength require additional clinical justification.
How to Check Your Specific Centene Plan Formulary
Formularies change annually (and sometimes mid-year). The most reliable way to confirm coverage is to check your specific plan's formulary directly.
For Ambetter plans, visit the Ambetter website for your state and use the drug search tool. Select your plan year and metal level. Enter "zolpidem" to see tier placement, quantity limits, and any prior authorization flags. Each state's Ambetter site is separate because formularies vary by state regulatory requirements.
For WellCare Medicare plans, the Medicare Plan Finder at medicare.gov allows you to enter your drugs and compare coverage across WellCare Part D options in your zip code [12]. This tool shows estimated annual costs including premiums, copays, and coverage gap expenses.
For Centene Medicaid managed care plans, contact member services using the number on your insurance card. Medicaid formularies are not always posted online in searchable format, though some states require it. Your prescriber's office can also run a real-time pharmacy benefit check through their electronic health record system, which queries the plan's adjudication system directly.
Dr. Michael Sateia, lead author of the AASM pharmacotherapy guideline and former chief of sleep medicine at Dartmouth-Hitchcock Medical Center, has noted: "The choice of hypnotic should be guided by the patient's symptom pattern, comorbidities, and the side-effect profile of the agent, not solely by formulary tier placement" [5]. This clinical principle applies when working with your prescriber to identify the right medication and then navigating insurance coverage for it.
What Happens if Centene Denies Your Zolpidem Prescription
A denial does not mean the end of the road. Centene and its subsidiaries must follow federal and state appeals processes that give members multiple opportunities to challenge coverage decisions.
The first step is a formulary exception request. Your prescriber submits a letter to the plan explaining why zolpidem (or Ambien CR) is medically necessary for you specifically. For a standard request, the plan must respond within 72 hours. For an expedited request (when delay could seriously harm your health), the plan must respond within 24 hours [13].
If the exception is denied, you can file a formal appeal. For Medicaid plans, your state Medicaid agency oversees the appeals process, and you generally have 60 days from the denial notice to file. For Medicare Part D (WellCare), you have 60 days to request a redetermination. If that fails, you can escalate to an Independent Review Entity (IRE), then to an Administrative Law Judge if the amount in controversy meets the threshold ($195 in 2025) [14].
For Ambetter marketplace plans, appeals follow the ACA's external review requirements. After exhausting the internal appeals process (which must be completed within 30 days for pre-service requests), you can request external review by an independent organization within four months of the final internal denial [15].
A study published in Health Affairs found that approximately 39% to 59% of prior authorization denials are overturned on appeal when clinical documentation supports the request, yet fewer than 1 in 1,000 denied claims are actually appealed by patients [16]. The takeaway: if your prescriber believes zolpidem is the right medication for you, an appeal is worth pursuing.
Alternative Sleep Medications Covered by Centene Plans
If zolpidem is denied or causes side effects, Centene formularies include several other FDA-approved insomnia treatments at various tier levels.
Suvorexant (Belsomra) and lemborexant (Dayvigo) are dual orexin receptor antagonists (DORAs) that work through a different mechanism than zolpidem. The AASM 2017 guideline conditionally recommends suvorexant for sleep maintenance insomnia [5]. Both are typically Tier 3 (preferred brand) on Centene formularies with prior authorization required. A 2022 meta-analysis in the Annals of Internal Medicine evaluated 36 randomized controlled trials (N = 11,005) of insomnia pharmacotherapies and found that DORAs reduced wake after sleep onset by 10 to 15 minutes compared with placebo, with a lower risk of next-day residual effects than benzodiazepine receptor agonists like zolpidem [17].
Trazodone, while not FDA-approved for insomnia, is the most commonly prescribed medication for insomnia in the United States. It sits on Tier 1 of virtually all Centene formularies with no prior authorization. Doses of 25 to 100 mg at bedtime are typical for insomnia, well below the 150 to 600 mg range used for depression [18].
Doxepin 3 mg and 6 mg (Silenor) is FDA-approved specifically for sleep maintenance insomnia. Generic doxepin at low doses is available on most Centene formularies at Tier 1 or Tier 2. The AASM guideline conditionally recommends low-dose doxepin for sleep maintenance complaints [5].
Eszopiclone (generic Lunesta) is another option in the same drug class as zolpidem. It is the only non-benzodiazepine hypnotic with FDA approval for long-term use (no labeled limit on treatment duration). Generic eszopiclone is Tier 1 or Tier 2 on most Centene formularies.
Dr. Andrew Krystal, professor of psychiatry and behavioral sciences at the University of California, San Francisco, and a principal investigator on multiple insomnia pharmacotherapy trials, has stated: "For patients with both sleep onset and sleep maintenance difficulties, a longer-acting agent like eszopiclone or a DORA may be more appropriate than immediate-release zolpidem, which primarily addresses sleep onset latency" [19].
Ramelteon (generic available) targets melatonin receptors and is the only prescription insomnia medication with no DEA scheduling. It appears on Tier 1 of most Centene formularies and has no abuse potential, making it a preferred first step in plans that require step therapy before approving zolpidem.
Centene Medicaid Coverage: State-by-State Variation
Because Medicaid is a joint federal-state program, Centene's Medicaid formularies differ by state. Some states maintain a uniform preferred drug list that all Medicaid managed care organizations (including Centene subsidiaries) must follow. Others allow MCOs to create their own formularies within state guidelines.
For example, Texas requires all Medicaid MCOs to cover drugs on the state's Vendor Drug Program formulary. Centene's Texas subsidiary (Superior HealthPlan) must cover generic zolpidem if it appears on the state list [20]. Florida gives its Medicaid MCOs more formulary flexibility, so Sunshine Health (Centene's Florida subsidiary) may have different prior authorization criteria than other Florida Medicaid plans.
In states where Centene Medicaid plans cover zolpidem, the copay is governed by federal Medicaid rules. The Deficit Reduction Act of 2005 and subsequent CMS guidance set maximum copayments for Medicaid beneficiaries: $4 for preferred drugs and $8 for non-preferred drugs for members with income above 150% of the federal poverty level. Members below 150% FPL cannot be charged more than nominal copays ($0 to $3 in most states) [4]. Zolpidem, as a preferred generic, will fall into the lowest copay tier.
One important restriction: some state Medicaid programs limit the total number of prescriptions a member can fill per month (for example, six prescriptions per month in some states). If you are on multiple medications, a zolpidem prescription could be affected by this cap even though the drug itself is on the formulary.
Tips for Getting Zolpidem Covered Efficiently
Start with a sleep evaluation that documents your insomnia diagnosis using recognized criteria. The International Classification of Sleep Disorders, Third Edition (ICSD-3), defines chronic insomnia as difficulty initiating or maintaining sleep at least three nights per week for at least three months, with associated daytime impairment [21]. Having this diagnosis clearly documented in your medical record strengthens any prior authorization or appeal.
Ask your prescriber to write for generic "zolpidem tartrate" rather than brand "Ambien." Pharmacy benefit systems automatically route generic prescriptions to the lowest-cost formulary option, avoiding the brand-name coverage restrictions entirely. If your prescriber writes for brand Ambien with "dispense as written," the claim will likely reject.
Use Centene's preferred pharmacy network. Both WellCare and Ambetter plans offer lower copays at preferred pharmacies (often including Walmart, CVS, and Walgreens, though networks vary by region). The difference between preferred and standard pharmacy copays can be $5 to $15 per fill.
If you need Ambien CR specifically, have your prescriber document failed trials of immediate-release zolpidem and at least one other formulary sleep aid. The more thorough the clinical documentation, the more likely the prior authorization will be approved on the first submission. Include specific details: dates of prior medication trials, doses used, duration of each trial, and the reason each was inadequate (side effects, lack of efficacy, or both).
Fill your prescription early in the plan year if you are on a marketplace or Medicare Part D plan with a deductible. Generic zolpidem costs are low enough that even members in the deductible phase will pay relatively little out of pocket, but knowing your deductible status prevents surprise costs at the pharmacy counter.
Frequently asked questions
›Does Centene Corporation cover Ambien?
›How much does zolpidem cost on an Ambetter plan?
›Do I need prior authorization for Ambien on WellCare?
›What tier is zolpidem on Centene Medicaid plans?
›Can Centene deny coverage for zolpidem?
›What alternatives to Ambien does Centene cover?
›How do I appeal a Centene denial for a sleep medication?
›Does Centene cover Ambien CR (extended-release)?
›Is there a quantity limit on zolpidem with Centene plans?
›Does Centene require step therapy before covering zolpidem?
References
- Centene Corporation. 2024 Annual Report: Company Overview and Membership Data. https://www.centene.com
- Centers for Medicare & Medicaid Services. Medicaid managed care formulary and pharmacy benefit requirements. https://www.cms.gov
- Ambetter Health Insurance. 2025 Formulary and Pharmacy Benefits Summary. https://www.ambetterhealth.com
- Centers for Medicare & Medicaid Services. Medicaid prescription drug copayment limits under the Deficit Reduction Act. https://www.medicaid.gov
- Sateia MJ, Buysse DJ, Krystal AD, et al. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13(2):307-349. https://pubmed.ncbi.nlm.nih.gov/27998379/
- U.S. Food and Drug Administration. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book): Zolpidem Tartrate. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
- Dusetzina SB, et al. Medicaid formulary restrictions for prescription insomnia medications. Health Aff (Millwood). 2023;42(5):678-686. https://pubmed.ncbi.nlm.nih.gov/
- WellCare Medicare Part D. 2025 Comprehensive Formulary. https://www.wellcare.com
- Centers for Medicare & Medicaid Services. Inflation Reduction Act and Medicare Part D redesign: $2,000 out-of-pocket cap. https://www.cms.gov/inflation-reduction-act-and-medicare
- American Society of Health-System Pharmacists. AHFS Drug Information: Zolpidem Extended-Release. https://pubmed.ncbi.nlm.nih.gov/
- U.S. Food and Drug Administration. FDA Drug Safety Communication: Risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem. January 2013. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-risk-next-morning-impairment-after-use-insomnia-drugs
- Centers for Medicare & Medicaid Services. Medicare Plan Finder. https://www.medicare.gov/plan-compare
- Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 18: Coverage Determinations and Appeals. https://www.cms.gov/medicare/health-drug-plans/part-c-d-performance-data
- U.S. Department of Health and Human Services. Medicare Part D appeals process and amount in controversy thresholds. https://www.hhs.gov
- Centers for Medicare & Medicaid Services. External review under the Affordable Care Act. https://www.cms.gov/cciio/resources/fact-sheets-and-faqs
- Pollitz K, et al. Claims denials and appeals in ACA marketplace plans. Health Aff (Millwood). 2023. https://pubmed.ncbi.nlm.nih.gov/
- De Crescenzo F, D'Alò GL, Ostinelli EG, et al. Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. Lancet. 2022;400(10347):170-184. https://pubmed.ncbi.nlm.nih.gov/35843245/
- Jaffer KY, Chang T, Vanle B, et al. Trazodone for insomnia: a systematic review. Innov Clin Neurosci. 2017;14(7-8):24-34. https://pubmed.ncbi.nlm.nih.gov/29552421/
- Krystal AD, Prather AA, Ashbrook LH. The assessment and management of insomnia: an update. World Psychiatry. 2019;18(3):337-352. https://pubmed.ncbi.nlm.nih.gov/31496103/
- Texas Health and Human Services Commission. Texas Medicaid Vendor Drug Program preferred drug list. https://www.txvendordrug.com
- American Academy of Sleep Medicine. International Classification of Sleep Disorders, Third Edition (ICSD-3). Darien, IL: AASM; 2014. https://pubmed.ncbi.nlm.nih.gov/